UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Does oral appliance efficacy in treating obstructive sleep apnea depend on the appliance specialist’s experience?

Sleep & breathing, 2024-03, Vol.28 (1), p.555-560

2024

Volltextzugriff (PDF)

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

Journal of the European Academy of Dermatology and Venereology, 2009-12, Vol.23 (12), p.1374-1382

2009

Volltextzugriff (PDF)

Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis

Journal of the European Academy of Dermatology and Venereology, 2009-08, Vol.23 (8), p.896-904

2009

Volltextzugriff (PDF)

Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial

Journal of the European Academy of Dermatology and Venereology, 2011-05, Vol.25 (5), p.559-564

2011

Volltextzugriff (PDF)

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab

Lupus, 2016-04, Vol.25 (4), p.346-354

2016

Volltextzugriff (PDF)

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens

Journal of the European Academy of Dermatology and Venereology, 2012-11, Vol.26 (11), p.1436-1443

2012

Volltextzugriff (PDF)

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial

BMJ, 2010-02, Vol.340 (feb02 2), p.c147-c147

2010

Volltextzugriff (PDF)

SAT0075 Systemic Lupus Erythematosus (SLE) in UK Primary Care: Severity at Onset and Progression over Time Using the UK Clinical Practice Research Datalink

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.617-617

2014

Volltextzugriff (PDF)

THU0414 The Incidence and Presentation of Systemic Lupus Erythematosus (SLE) in UK Primary Care Using the UK Clinical Practice Research Datalink (CPRD)

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.325-325

2014

Volltextzugriff (PDF)

AB1331 The impact of systemic lupus erythematosus on employment loss from a population-based cohort

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.714-714

2013

Volltextzugriff (PDF)

Familial occurrence of systemic sclerosis, rheumatoid arthritis and other immunological disorders: report of two kindreds with study of HLA antigens and review of the literature

Clinical and experimental rheumatology, 1989-05, Vol.7 (3), p.229

1989

Volltextzugriff (PDF)

PSY45 PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN EUROPEAN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS

Value in health, 2008, Vol.11 (6), p.A643-A643

2008

Volltextzugriff (PDF)

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study: Patient-reported outcomes in psoriasis patients treated with etanercept

Journal of the European Academy of Dermatology and Venereology, 2009-12, Vol.23 (12), p.1374-1382

2009

Volltextzugriff (PDF)

Corticosteroid Use Across 52 Weeks Of Belimumab Therapy In Patients With Systemic Lupus Erythematosus: Combined Analyses From The BLISS Trials

ARTHRITIS AND RHEUMATISM, 2013, Vol.65, p.S672

2013

Volltextzugriff (PDF)

Cytokine-associated neutrophil extracellular traps and antinuclear antibodies in Plasmodium falciparum infected children under six years of age

Malaria journal, 2008-02, Vol.7 (1), p.41-41, Article 41

2008

Volltextzugriff (PDF)

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care

Lupus, 2016-06, Vol.25 (7), p.699-709

2016

Volltextzugriff (PDF)

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA

Lupus science & medicine, 2016-01, Vol.3 (1), p.e000118-e000118

2016

Volltextzugriff (PDF)

SAT0115 Effect of biological disease modifying anti-rheumatic drugs (BDMARDS) on cardio vascular disease (CVD) risk in ra patients:three years results from a canadian cohort

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.812

2017

Volltextzugriff (PDF)

Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel

Lupus, 2014-09, Vol.23 (10), p.1006-1013

2014

Volltextzugriff (PDF)

The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics

Journal of the European Academy of Dermatology and Venereology, 2010-05, Vol.24 (5), p.548-554

2010

Volltextzugriff (PDF)

FRI0506 Hla profiles and their associations with disease phenotypes in a canadian psoriatic arthritis (PSA) cohort

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.680

2017

Volltextzugriff (PDF)

FRI0153 Comparison of cardiovascular risk in patients with rheumatoid arthritis treated with biologics versus methotrexate: results at 24-months of follow-up

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.539

2017

Volltextzugriff (PDF)

SAT0027 Baseline Factors That PREDICT High Blys Levels (≥2 NG/ML) in Patients with Systemic Lupus Erythematosus: Data from the BLISS Trials

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.598-598

2014

Volltextzugriff (PDF)

FRI0374 Outcomes in Systemic Lupus Erythematosus Patients with High Disease Activity Treated with Belimumab: 18 Month Results from the US Observe Study

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.522

2014

Volltextzugriff (PDF)

OP0186 5-Year Organ Damage Accrual and Safety in Patients with Sle Treated with Belimumab Plus Standard of Care

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.142-142

2015

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Englisch
(53)
Französisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(23)
Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Male
(17)
Female
(15)
Middle Aged
(11)
Adult
(10)
Psoriasis
(9)
Treatment Outcome
(9)
Dermatology
(8)
Etanercept
(7)
Biological And Medical Sciences
(6)
Medical Sciences
(6)
Psoriasis - Drug Therapy
(6)
Quality Of Life
(6)
Rheumatology
(6)
Severity Of Illness Index
(6)
Immunoglobulin G - Therapeutic Use
(5)
Receptors, Tumor Necrosis Factor - Therapeutic Use
(5)
Systemic Lupus Erythematosus
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Does oral appliance efficacy in treating obstructive sleep apnea depend on the appliance specialist’s experience?

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis

Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab

Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial

SAT0075 Systemic Lupus Erythematosus (SLE) in UK Primary Care: Severity at Onset and Progression over Time Using the UK Clinical Practice Research Datalink

THU0414 The Incidence and Presentation of Systemic Lupus Erythematosus (SLE) in UK Primary Care Using the UK Clinical Practice Research Datalink (CPRD)

AB1331 The impact of systemic lupus erythematosus on employment loss from a population-based cohort

Familial occurrence of systemic sclerosis, rheumatoid arthritis and other immunological disorders: report of two kindreds with study of HLA antigens and review of the literature

PSY45 PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN EUROPEAN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study: Patient-reported outcomes in psoriasis patients treated with etanercept

Corticosteroid Use Across 52 Weeks Of Belimumab Therapy In Patients With Systemic Lupus Erythematosus: Combined Analyses From The BLISS Trials

Cytokine-associated neutrophil extracellular traps and antinuclear antibodies in Plasmodium falciparum infected children under six years of age

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA

SAT0115 Effect of biological disease modifying anti-rheumatic drugs (BDMARDS) on cardio vascular disease (CVD) risk in ra patients:three years results from a canadian cohort

Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel

The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics

FRI0506 Hla profiles and their associations with disease phenotypes in a canadian psoriatic arthritis (PSA) cohort

FRI0153 Comparison of cardiovascular risk in patients with rheumatoid arthritis treated with biologics versus methotrexate: results at 24-months of follow-up

SAT0027 Baseline Factors That PREDICT High Blys Levels (≥2 NG/ML) in Patients with Systemic Lupus Erythematosus: Data from the BLISS Trials

FRI0374 Outcomes in Systemic Lupus Erythematosus Patients with High Disease Activity Treated with Belimumab: 18 Month Results from the US Observe Study

OP0186 5-Year Organ Damage Accrual and Safety in Patients with Sle Treated with Belimumab Plus Standard of Care

Suchergebnisse filtern